These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35445350)

  • 1. Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
    Frechen S; Rostami-Hodjegan A
    Pharm Res; 2022 Aug; 39(8):1733-1748. PubMed ID: 35445350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.
    Frechen S; Solodenko J; Wendl T; Dallmann A; Ince I; Lehr T; Lippert J; Burghaus R
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):633-644. PubMed ID: 33946131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction.
    Prieto Garcia L; Lundahl A; Ahlström C; Vildhede A; Lennernäs H; Sjögren E
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1194-1209. PubMed ID: 35722750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute.
    Smits A; De Cock P; Vermeulen A; Allegaert K
    Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):25-34. PubMed ID: 30554542
    [No Abstract]   [Full Text] [Related]  

  • 8. In-depth analysis of patterns in selection of different physiologically-based pharmacokinetic modeling tools: Part II - Assessment of model reusability and comparison between open and non-open source-code software.
    Aldibani HKA; Rajput AJ; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2023 Aug; 44(4):292-300. PubMed ID: 37083940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Pharmacokinetics Model in Pregnancy: A Regulatory Perspective on Model Evaluation.
    Coppola P; Kerwash E; Cole S
    Front Pediatr; 2021; 9():687978. PubMed ID: 34249817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 11. Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator.
    Ezuruike U; Zhang M; Pansari A; De Sousa Mendes M; Pan X; Neuhoff S; Gardner I
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):805-821. PubMed ID: 35344639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teaching of drug disposition using physiologically based pharmacokinetic modeling software: GastroPlus as an educational tool.
    Morningstar-Kywi N; Morris DN; Romero RM; Haworth IS
    Adv Physiol Educ; 2023 Dec; 47(4):718-725. PubMed ID: 37471218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
    Yun YE; Edginton AN
    J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care.
    van Borselen MD; Sluijterman LAÆ; Greupink R; de Wildt SN
    Clin Pharmacokinet; 2024 Mar; 63(3):343-355. PubMed ID: 38361163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
    Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
    Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.